A Philadelphia cell therapy developer has closed a $25 million ... to the $15 million financing it announced last November.
Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12 ... The latest round was ...
The firm will use the funding to support the Phase I trial of its CAR T-cell therapy, VIPER-101, in lymphoma patients.
WWII veteran Richard Young captures history through lens of a camera Sometimes, the best way that history can be told is through the lens of a camera.